EUVIMEDEUVIMED entdecken
Crossref

Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction

Meghamsh Kanuparthy iD, Dwight D Harris, Mark Broadwin, Christopher Stone, Jad Hamze, Keertana Yalamanchili iD, Sharif Sabe, Frank W Sellke

Asian Cardiovascular and Thoracic Annals · 2025

DOI: 10.1177/02184923251352222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Cardiovascular and Thoracic Annals, 2025. Verfasst von Meghamsh Kanuparthy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown Univ…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Ventricular Function, Left, Canagliflozin, Pulmonary Fibrosis. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Heart, Lung, and Blood Institute, Brown University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Left heart failure is the most common cause of pulmonary hypertension and increases morbidity and mortality. We investigate the use of canagliflozin, an antidiabetic Sodium-glucose Cotransporter-2 Inhibitor, which is first-line therapy in congestive heart failure, on pulmonary fibrosis in a porcine model of chronic myocardial ischemia. Methodology Sixteen Yorkshire swine, eight in a normal diet control arm (NDC) and eight in the canagliflozin arm (CAN), underwent left thoracotomy and ameroid constrictor placement on the left circumflex artery. Seven weeks after placement, the swine underwent harvest procedure. During harvest, left ventricular contractility was quantified by direct left ventricular pressure-volume loops. Protein expression was quantified by immunoblotting and Masson's trichrome staining was utilized to assess perivascular collagen deposition.

Results

Analysis of left ventricular ejection fraction demonstrated no significant difference between CAN and NDC. Western blot analysis demonstrated increases in TGFβ signaling pathways with decreased free TGFβ and TGFβ monomers in CAN pigs ( p < 0.01). Downstream mediators of TGFβ were also increased in NDC with an increase in phospho-SMAD2/3 activity ( p = 0.005). Masson's Trichrome analysis of lung tissue demonstrated a trend toward reduced perivascular collagen deposition in CAN swine lungs ( p = 0.086).

Conclusions

Canagliflozin ameliorates chronic fibrotic changes related to pulmonary hypertension in left ventricular failure. While there was a strong trend toward significance in histologic analysis, this may be limited by the duration of our model. Western blot analysis, however, demonstrates that CAN's modulation of TGFβ signaling pathways may play a role in the management of secondary pulmonary hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsVentricular Function, LeftCanagliflozinPulmonary FibrosisLungVentricular Dysfunction, LeftAntifibrotic AgentsAnimalsDisease Models, AnimalSus scrofaTransforming Growth Factor betaSignal TransductionSmad2 ProteinSmad3 ProteinSwineStroke VolumeCollagen

Stichwörter der Autor:innen

Myocardial ischemiacardiacischemic cardiomyopathylung—otherpulmonary arteries/veins (incl normal and diseased)pulmonary vascular resistance/hypertensionthoracic

Substanzen

Sodium-Glucose Transporter 2 InhibitorsCanagliflozinTransforming Growth Factor betaAntifibrotic AgentsSmad2 ProteinSmad3 ProteinCollagen

Autor:innen und Institutionen

  • Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA.

ORCID-Profile: Meghamsh Kanuparthy, Keertana Yalamanchili

Förderung

  • National Heart, Lung, and Blood Institute
  • Brown University

Zitieren

APA

Kanuparthy, M., Harris, D. D., Broadwin, M., Stone, C., Hamze, J., Yalamanchili, K., Sabe, S., & Sellke, F. W. (2025). Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction. Asian Cardiovascular and Thoracic Annals. https://doi.org/10.1177/02184923251352222

Vancouver

Kanuparthy M, Harris DD, Broadwin M, Stone C, Hamze J, Yalamanchili K, et al. Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction. Asian Cardiovascular and Thoracic Annals. 2025. doi:10.1177/02184923251352222

BibTeX
@article{Kanuparthy2025,
  author = {Kanuparthy, Meghamsh and Harris, Dwight D and Broadwin, Mark and Stone, Christopher and Hamze, Jad and Yalamanchili, Keertana and Sabe, Sharif and Sellke, Frank W},
  title = {Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction},
  journal = {Asian Cardiovascular and Thoracic Annals},
  year = {2025},
  doi = {10.1177/02184923251352222}
}
Kostenlos starten →